AARD — Aardvark Therapeutics, Inc. Common Stock

Open full analysis

Chart, dilution, float and news for AARD in the TickerWise workspace.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 28
• Website: https://www.aardvarktherapeutics.com

Latest SEC filings for AARD

• 2026-10-088-K
• 2026-08-178-K
• 2026-08-118-K
• 2026-08-1110-Q
• 2026-07-10ARS
• 2026-06-128-K
• 2026-05-148-K
• 2026-05-0710-Q
• 2026-05-078-K
• 2026-04-06EFFECT

Latest AARD news

• 2026-10-23Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials Read article
• 2026-10-21Aardvark Therapeutics(AARD) Stock Options Chain | Quotes & News Read article
• 2026-10-21All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy Read article
• 2026-10-19Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Hub Group, Inc. (NASDAQ: HUBG); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigati Read article
• 2026-10-13Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD Read article
• 2026-10-13Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm Read article
• 2026-10-13CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 Read article
• 2026-10-12AARD Deadline: AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit Read article

Open full analysis

Educational tool only — not investment advice.